NO325945B1 - Anvendelse av hyaluronidase ved fremstilling av et medikament for behandling av tilstander av interstitielt odem i sammenheng med organtransplantasjon forbundet med et okt lokalt innhold av hyaluronan i bindevevet hos et pattedyr. - Google Patents

Anvendelse av hyaluronidase ved fremstilling av et medikament for behandling av tilstander av interstitielt odem i sammenheng med organtransplantasjon forbundet med et okt lokalt innhold av hyaluronan i bindevevet hos et pattedyr. Download PDF

Info

Publication number: NO325945B1
Authority: NO; Norway
Prior art keywords: hyaluronidase; hyaluronan; treatment; mammal; connective tissue
Prior art date: 1996-08-26

Application number

NO19990898A

Other languages

English (en)

Norwegian (no)

Other versions

NO990898L (no

NO990898D0 (no

Inventor

Gunnar Tufveson

Roger Hallgren

Cecilia Johnsson

Jan Wahlberg

Original Assignee

Applet Mbj Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-26

Filing date

1999-02-25

Publication date

2008-08-25

1999-02-25 Application filed by Applet Mbj Ab filed Critical Applet Mbj Ab

1999-02-25 Publication of NO990898L publication Critical patent/NO990898L/no

1999-02-25 Publication of NO990898D0 publication Critical patent/NO990898D0/no

2008-08-25 Publication of NO325945B1 publication Critical patent/NO325945B1/no

Links

108010003272 Hyaluronate lyase Proteins 0.000 title claims abstract description 43
102000001974 Hyaluronidases Human genes 0.000 title claims abstract description 43
229960002773 hyaluronidase Drugs 0.000 title claims abstract description 43
229920002674 hyaluronan Polymers 0.000 title claims abstract description 39
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 title claims abstract description 38
229940099552 hyaluronan Drugs 0.000 title claims abstract description 38
210000000056 organ Anatomy 0.000 title claims abstract description 26
206010030113 Oedema Diseases 0.000 title claims abstract description 22
239000003814 drug Substances 0.000 title claims abstract description 13
241000124008 Mammalia Species 0.000 title claims abstract description 12
210000002808 connective tissue Anatomy 0.000 title claims abstract description 8
238000004519 manufacturing process Methods 0.000 title claims abstract description 5
238000002054 transplantation Methods 0.000 title claims description 14
230000037396 body weight Effects 0.000 claims abstract description 18
229940079593 drug Drugs 0.000 claims abstract description 17
238000002360 preparation method Methods 0.000 claims description 6
230000003449 preventive effect Effects 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
230000015572 biosynthetic process Effects 0.000 abstract description 7
238000000034 method Methods 0.000 abstract description 5
238000003786 synthesis reaction Methods 0.000 abstract description 4
230000009885 systemic effect Effects 0.000 abstract description 3
210000002216 heart Anatomy 0.000 description 15
241000700159 Rattus Species 0.000 description 13
210000001519 tissue Anatomy 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
238000009825 accumulation Methods 0.000 description 10
241001465754 Metazoa Species 0.000 description 9
210000003734 kidney Anatomy 0.000 description 8
208000010125 myocardial infarction Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000003306 harvesting Methods 0.000 description 4
102000036211 hyaluronic acid binding proteins Human genes 0.000 description 4
108091010998 hyaluronic acid binding proteins Proteins 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
206010000891 acute myocardial infarction Diseases 0.000 description 3
230000027455 binding Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
230000000302 ischemic effect Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
238000000585 Mann–Whitney U test Methods 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
238000011552 rat model Methods 0.000 description 2
230000008961 swelling Effects 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
HPYYIBPNNXXEAA-IRBJBBIRSA-N (2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid;n-[(3r,4r,5s,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O.CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O HPYYIBPNNXXEAA-IRBJBBIRSA-N 0.000 description 1
OBFSQMXGZIYMMN-UHFFFAOYSA-N 3-chloro-2-hexadecylpyridine Chemical compound CCCCCCCCCCCCCCCCC1=NC=CC=C1Cl OBFSQMXGZIYMMN-UHFFFAOYSA-N 0.000 description 1
206010001889 Alveolitis Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000239366 Euphausiacea Species 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
241000545744 Hirudinea Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000011316 allogeneic transplantation Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
229960001668 cefuroxime Drugs 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000002497 edematous effect Effects 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000035876 healing Effects 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000006749 inflammatory damage Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
210000002570 interstitial cell Anatomy 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
208000037906 ischaemic injury Diseases 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
238000011694 lewis rat Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000002559 palpation Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000003761 preservation solution Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
210000001147 pulmonary artery Anatomy 0.000 description 1
230000010349 pulsation Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000002381 testicular Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011870 unpaired t-test Methods 0.000 description 1
229940046284 zinacef Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO19990898A 1996-08-26 1999-02-25 Anvendelse av hyaluronidase ved fremstilling av et medikament for behandling av tilstander av interstitielt odem i sammenheng med organtransplantasjon forbundet med et okt lokalt innhold av hyaluronan i bindevevet hos et pattedyr. NO325945B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9603082A SE509350C2 (sv)	1996-08-26	1996-08-26	Användning av hyaluronidas vid behandling av interstitiellt ödem i samband med organtransplantation
PCT/SE1997/001313 WO1998008538A1 (en)	1996-08-26	1997-07-24	Use of hyaluronidase

Publications (3)

Publication Number	Publication Date
NO990898L NO990898L (no)	1999-02-25
NO990898D0 NO990898D0 (no)	1999-02-25
NO325945B1 true NO325945B1 (no)	2008-08-25

Family

ID=20403654

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19990898A NO325945B1 (no)	1996-08-26	1999-02-25	Anvendelse av hyaluronidase ved fremstilling av et medikament for behandling av tilstander av interstitielt odem i sammenheng med organtransplantasjon forbundet med et okt lokalt innhold av hyaluronan i bindevevet hos et pattedyr.

Country Status (10)

Country	Link
EP (1)	EP0942745B1 (de)
JP (1)	JP4087453B2 (de)
AT (1)	ATE224729T1 (de)
AU (1)	AU721141B2 (de)
CA (1)	CA2262637C (de)
DE (1)	DE69715898T2 (de)
ES (1)	ES2183206T3 (de)
NO (1)	NO325945B1 (de)
SE (1)	SE509350C2 (de)
WO (1)	WO1998008538A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2413492T3 (es)	2008-10-14	2013-07-16	Burgard, Gunther, Dr.	Uso de hialuronidasa para la prevención o el tratamiento de la hipertensión arterial
EP2392325A1 (de)	2010-06-04	2011-12-07	Universitätsklinikum Münster	Neue Verbindungen zur Prävention und/oder Behandlung von Osteoarthrose

1996
- 1996-08-26 SE SE9603082A patent/SE509350C2/sv not_active IP Right Cessation
1997
- 1997-07-24 CA CA002262637A patent/CA2262637C/en not_active Expired - Fee Related
- 1997-07-24 AU AU37908/97A patent/AU721141B2/en not_active Ceased
- 1997-07-24 DE DE69715898T patent/DE69715898T2/de not_active Expired - Lifetime
- 1997-07-24 WO PCT/SE1997/001313 patent/WO1998008538A1/en not_active Ceased
- 1997-07-24 ES ES97934835T patent/ES2183206T3/es not_active Expired - Lifetime
- 1997-07-24 EP EP97934835A patent/EP0942745B1/de not_active Expired - Lifetime
- 1997-07-24 JP JP51152798A patent/JP4087453B2/ja not_active Expired - Fee Related
- 1997-07-24 AT AT97934835T patent/ATE224729T1/de not_active IP Right Cessation
1999
- 1999-02-25 NO NO19990898A patent/NO325945B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
SE9603082L (sv)	1998-02-27
ES2183206T3 (es)	2003-03-16
SE509350C2 (sv)	1999-01-18
EP0942745B1 (de)	2002-09-25
CA2262637A1 (en)	1998-03-05
CA2262637C (en)	2004-03-30
JP2000517315A (ja)	2000-12-26
NO990898L (no)	1999-02-25
AU3790897A (en)	1998-03-19
ATE224729T1 (de)	2002-10-15
DE69715898T2 (de)	2004-01-22
EP0942745A1 (de)	1999-09-22
JP4087453B2 (ja)	2008-05-21
AU721141B2 (en)	2000-06-22
DE69715898D1 (de)	2002-10-31
NO990898D0 (no)	1999-02-25
SE9603082D0 (sv)	1996-08-26
WO1998008538A1 (en)	1998-03-05

Legal Events

Date	Code	Title	Description
2012-02-20	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
Flack et al.	2000	Does cardioplegia type affect outcome and survival in patients with advanced left ventricular dysfunction
Pangburn	2000	Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement
Dos Santos et al.	2002	Mechanisms by which opening the mitochondrial ATP-sensitive K+ channel protects the ischemic heart
Fan et al.	2020	Cardioprotective effect of the polysaccharide from Ophiopogon japonicus on isoproterenol-induced myocardial ischemia in rats
Adrie et al.	2004	Postresuscitation disease after cardiac arrest: a sepsis-like syndrome?
Liu et al.	2009	Immediate postconditioning during reperfusion attenuates intestinal injury
Stevens et al.	1992	Circulating von Willebrand factor in inflammatory bowel disease.
Greiffenstein et al.	2007	Alcohol binge before trauma/hemorrhage impairs integrity of host defense mechanisms during recovery
Arda-Pirincci et al.	2020	Galectin-1 reduces the severity of dextran sulfate sodium (DSS)-induced ulcerative colitis by suppressing inflammatory and oxidative stress response
Kølsen‐Petersen	2004	Immune effect of hypertonic saline: fact or fiction?
Takhtfooladi et al.	2016	Effects of N-acetylcysteine and pentoxifylline on remote lung injury in a rat model of hind-limb ischemia/reperfusion injury
Ottillinger et al.	2001	Rational therapy of chronic venous insufficiency–chances and limits of the therapeutic use of horse-chestnut seeds extract
Vanoverschelde et al.	1994	The relative importance of myocardial energy metabolism compared with ischemic contracture in the determination of ischemic injury in isolated perfused rabbit hearts.
Tsimoyiannis et al.	1993	Trimetazidine for prevention of hepatic injury induced by ischaemia and reperfusion in rats
Li et al.	2019	Alpha-1 adrenergic receptor agonist phenylephrine inhibits sepsis-induced cardiomyocyte apoptosis and cardiac dysfunction via activating ERK1/2 signal pathway
JP2002541113A (ja)	2002-12-03	免疫調節ポリマー
NO325945B1 (no)	2008-08-25	Anvendelse av hyaluronidase ved fremstilling av et medikament for behandling av tilstander av interstitielt odem i sammenheng med organtransplantasjon forbundet med et okt lokalt innhold av hyaluronan i bindevevet hos et pattedyr.
Di Giorno et al.	2006	Beneficial effect of N-acetyl-cysteine on renal injury triggered by ischemia and reperfusion
Whitney et al.	1961	Apparent insulin activity in a fibrosarcoma associated with spontaneous hypoglycemia
Raghu et al.	1999	Protective effect of intravenous magnesium in acute myocardial infarction following thrombolytic therapy
US6572855B1 (en)	2003-06-03	Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation
Weissmann	1987	Pathogenesis of inflammation: Effects of the pharmacological manipulation of arachidonic acid metabolism on the cytological response to inflammatory stimuli
Hara et al.	1997	Treatment of crush syndrome patients following the great Hanshin earthquake
Kinoshita et al.	1991	Delayed time to peak serum myoglobin level as an indicator of cardiac dysfunction following open heart surgery
van Rossum et al.	1973	The net extrusion of calcium and its temporal relation to the accumulation of potassium in slices of rat liver and of Morris hepatomata 5123tc and 3924A